Is Mounjaro Meant to Be Taken Long Term?

The trial data that framed how long 'long term' actually means

The SURMOUNT-1 trial, published in the New England Journal of Medicine, ran for 72 weeks and enrolled 2,539 adults with obesity but without type 2 diabetes. At the highest dose, participants lost around 20–21% of their body weight on average. That kind of result takes time to accumulate, and the trial was deliberately long to capture it. A follow-on study then withdrew tirzepatide after the treatment period and tracked what happened next: weight regain was substantial, reinforcing what the biology would predict. Tirzepatide quiets the hormonal signals that drive appetite; stop it, and those signals return.

None of this means people must stay on Mounjaro indefinitely. It means the decision is a clinical one, revisited regularly, not settled on day one. Our clinical team reviews every repeat order individually for exactly this reason.

One misconception worth laying to rest gently: some people assume that if the medicine is 'working', they can eventually taper off and maintain the result through diet alone. For some that may be true; for most, the evidence suggests the appetite-regulating effect is tied to the medicine being present. A prescriber is the right person to test that assumption for each patient.

What NICE's tirzepatide guidance says about stopping versus continuing

NICE's appraisal of tirzepatide, TA1026, includes a practical continuation criterion: if someone has not lost at least 5% of their body weight after six months on the highest dose they can tolerate, the prescriber should review whether ongoing treatment is appropriate. That threshold matters because it distinguishes a medicine that is working from one that is not, and it protects people from continuing a treatment that carries side-effect risk without delivering benefit.

Beyond that checkpoint, TA1026 does not set a maximum treatment length. Contrast this with NICE's recommendation for semaglutide (Wegovy), which specifies a maximum of two years in the NHS context. Tirzepatide carries no equivalent time ceiling in its guidance. That distinction is worth knowing if you are comparing your options, though the right duration for any individual is always a conversation with a clinician rather than a rule read off a page.

For a fuller look at what the studies say about extended use, our summary of long-term Mounjaro studies covers the trial programme in more depth.

Safety monitoring over time, what the Black Triangle means for patients

Mounjaro carries the Black Triangle (▼) symbol, which means the MHRA requires enhanced post-marketing surveillance. This is standard for newer medicines and does not signal unusual danger; it signals that regulators want more real-world data to sit alongside the trial evidence. For patients on long-term treatment, it is a meaningful reassurance: adverse effects picked up across the prescribing population feed back into clinical guidance quickly.

Side effects most commonly cluster at treatment initiation and after dose increases, nausea, loose stools, constipation, reflux, and fatigue are the ones people mention most. They tend to settle within days to a couple of weeks for most patients. Long-term tolerability data from SURMOUNT is broadly reassuring, though the full picture of very-extended use continues to build through post-marketing follow-up, and our page on what Mounjaro long term actually involves sets out what that evidence currently shows. The NHS tirzepatide medicines page summarises the known safety profile clearly.

If you develop severe or persistent stomach pain that reaches through to your back, seek medical help promptly, this requires assessment to rule out pancreatitis, an infrequent but serious risk flagged for GLP-1 medicines. Any suspected side effect can be reported at the MHRA's Yellow Card scheme.

Thinking about what long-term effects might mean for you personally? Our page on long-term effects of Mounjaro goes into more detail.

Private treatment and what ongoing prescribing looks like at nume

On the NHS, tirzepatide access follows the phased rollout under NICE TA1026, criteria are specific and many people either do not yet qualify or face long waits. Private prescribing through a regulated service like nume (sorry, like nume) operates under the same licensed eligibility criteria (adults, BMI 30 or above, or 27-plus with a weight-related health condition), with every repeat order clinically reviewed before it is dispensed. There is no auto-renewal; a prescriber looks at the evidence of your response each time.

If you are already on treatment elsewhere and considering switching, or if you want to understand what a private prescription for Mounjaro actually costs, our Mounjaro pricing page explains what a single transparent price includes. For broader context on how tirzepatide works and what it is licensed for, including details on the tirzepatide intramuscular administration route, the tirzepatide overview is the right starting point.

Long-term treatment is a reasonable expectation for many people on Mounjaro. Whether it is right for you is a clinical question. Check your eligibility and speak to our prescribers through a free consultation.